The European Validation Authority EURL ECVAM offers users open access to its High-Throughput Testing laboratory.
Using heart organoids, researchers from the Genomic Medicine Center and Children's Mercy Research Institute, the University of Missouri-Kansas City School of Medicine and the University of Kansas Medical Center in Kansas City have demonstrated the efficacy of their antisense oligonucleotides in patients.
What specifically happens when developing nerve cells are exposed to “chronic” stress has been investigated by researchers at the Max Planck Institute of Psychiatry in Munich using cell models of the developing brain.
For research purposes, the syphilis bacterium (Treponema pallidum subsp. pallidum) could so far only be propagated in laboratory animals, especially rabbits. US researchers have now developed a method that enables the pathogen to be cultivated in cell cultures.
With his AI-supported platform “EmbryoNet-AI”, Professor Dr. Patrick Müller, an expert in developmental biology at the Department of Biology at University of Constance, aims to make drug research more efficient: Faster, cheaper and more accurate tests should replace animal testing.
The European Partnership for Alternative Approaches to Animal Testing (EPAA) supports students and young scientists with outstanding work in the field of alternative approaches for attending a high-profile scientific event. The deadline for participation in MPS World summit as well as for the SETAC congress is 14 February 2025.
A group of Republican and Democratic senators has reintroduced a bill urging the Food and Drug Administration (FDA) to adopt modern alternatives to animal testing.
At the end of January, an ESAC statement was published following an evaluation of the in vitro test methods “Reconstructed human Skin (RS) Comet” and “Micronucleus (RSMN)” for the assessment of genotoxicity. The assessments appear promising.
The Volkswagen Foundation is funding the development of the service platform “Primary Tissue Pipeline” for two years. The service platform facilitates access to primary human tissue for researchers at Charité/BIH, thus improving research opportunities at Charité.
A study published in Nature suggests that lab-grown organoids can help predict the treatment effects of genetic drugs made from RNA for people with rare diseases.